Carmen Coxon
Principle Scientist & MHRA-GAMRIF Team Lead Medicines & Healthcare Products Regulatory Agency (MHRA)
Seminars
Thursday 26th March 2026
Panel Discussion: Building a Unified Global Framework to Enable Scalable Phage Development, Investment Confidence & Market Access
9:30 am
- Comparing evolving regulatory approaches across regions to identify opportunities for alignment that de-risk development for investors
- Evaluating how harmonised guidance could accelerate approval timelines, reduce duplicated effort and strengthen the commercial case for phage therapies
- Exploring how global partnerships, data-sharing initiatives and transparent evidence standards can unlock greater investment, set new regulatory precedents and enable scalable, sustainable phage innovation
Thursday 26th March 2026
Charting Realistic Regulatory Pathways for Phage Development in a Changing Global Landscape
10:00 am
- Practical guidance on how innovators can work with regulators early to shape suitable pathways for phage products across human, veterinary and food settings, with clarity on licensed and unlicensed routes and how expectations differ across regions
- Insight into MHRA activities that support the field, including landscape mapping, communication tools tailored for developers, standards development and lessons learned from the UK government inquiry and its outcomes
- Why global market access needs early planning, with examples from low and middle income countries that highlight regulatory variation, adoption barriers and strategic routes that enable developers to reach the markets that need these products most
Wednesday 25th March 2026
Charting Realistic Regulatory Pathways for Phage Development in a Changing Global Landscape
10:00 am
- Practical guidance on how innovators can work with regulators early to shape suitable pathways for phage products across human, veterinary and food settings, with clarity on licensed and unlicensed routes and how expectations differ across regions
- Insight into MHRA activities that support the field, including landscape mapping, communication tools tailored for developers, standards development and lessons learned from the UK government inquiry and its outcomes
- Why global market access needs early planning, with examples from low and middle income countries that highlight regulatory variation, adoption barriers and strategic routes that enable developers to reach the markets that need these products most
